Important takeaways in breast cancer from ESMO 2022
Click Here to Manage Email Alerts
In this video, Erica L. Mayer, MD, MPH, discusses important takeaways from breast cancer sessions at this year’s European Society for Medical Oncology Congress.
“ESMO 2022 was a terrific conference,” Mayer, director of clinical research and physician with Dana-Farber Cancer Center and associate professor of medicine with Harvard Medical School, said. “[It was] wonderful to be together again.”
She highlighted three important presentations in breast cancer that will help clinicians “understand how we can use existing drugs,” expanding their use and selecting the appropriate patients for the right treatment.
The first abstract Mayer discussed was “encouraging” interim data from MONARCH-3, which investigated the addition of abemaciclib (Verzenio, Eli Lilly) to a nonsteroidal aromatase inhibitor in patients with hormone receptor-positive, HER2-negative advanced breast cancer.
“Perhaps, when we approach a patient, we want to be thinking not only about the survival benefits but also what the side effect profile is and what’s going to be the right fit for the patient,” she explained.
Mayer also noted takeaways from TROPiCS-02, a phase 3 study comparing sacituzumab govitecan (Trodelvy, Gilead) with treatment of physician's choice in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
“I found this data really important and interesting because it’s really showing us the benefit of this new tool for pretreated metastatic hormone receptor-positive disease,” she said.
Finally, Mayer highlighted two presentations that investigated the use of oral selective estrogen receptor degrader (SERD) endocrine therapy for metastatic breast cancer.
References:
- Goetz MP, et al. Abstract LBA15. Presented at: European Society for Medical Oncology Congress. Sept. 9-13, 2022; Paris.
- Martin Jimenez M, et al. Abstract 211MO. Presented at: European Society for Medical Oncology Congress. Sept. 9-13, 2022; Paris.
- Rugo HS, et al. Abstract LBA76. Presented at: European Society for Medical Oncology Congress. Sept. 9-13, 2022; Paris.
- Tolaney SM, et al. Abstract 212MO. Presented at: European Society for Medical Oncology Congress. Sept. 9-13, 2022; Paris.
Collapse
Click Here to Manage Email Alerts